TargetMol

Decamethonium iodide

Product Code:
 
TAR-T21099
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T21099-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21099-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21099-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Decamethonium is a neuromuscular blocking agent or depolarizing muscle relaxant, and is used in anesthesia to induce paralysis.
CAS:
1420-40-2
Formula:
C16H38I2N2
Molecular Weight:
512.3
Purity:
0.98
SMILES:
[N+](CCCCCCCCCC[N+](C)(C)C)(C)(C)C.[IH-].[IH-]

References

1. Rosenberry TL, Brazzolotto X, Macdonald IR, Wandhammer M, Trovaslet-Leroy M, Darvesh S, Nachon F. Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study. Molecules. 2017 Nov 29;22(12). pii: E2098. doi: 10.3390/molecules22122098. PubMed PMID: 29186056; PubMed Central PMCID: PMC6149722. 2. Fuss J, Palii V, Voloboyeva A. Evaluating the Effectivenes of Antiseptic Solution Decasan in Treatment of Necrotic Soft Tisue Diseases. Pol Przegl Chir. 2016 Oct 1;88(5):233-237. doi: 10.1515/pjs-2016-0058. PubMed PMID: 27811344. 3. Dym O, Song W, Felder C, Roth E, Shnyrov V, Ashani Y, Xu Y, Joosten RP, Weiner L, Sussman JL, Silman I. The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex. Protein Sci. 2016 Jun;25(6):1096-114. doi: 10.1002/pro.2923. Epub 2016 Mar 28. PubMed PMID: 26990888; PubMed Central PMCID: PMC4941771. 4. Nazarchuk OA. [?NTISEPTICS: MODERN STRATEGY OF STRUGGLE WITH CAUSING AGENTS OF THE ?NFECTION COMPLICATIONS]. Klin Khir. 2016;(9):59-61. Ukrainian. PubMed PMID: 30265488.